GlassScriptPhysician profile
Nicholas Guy Ross
NPI 1396240040
$2,264.47
in general payments reported to CMS, 2019-2025
26 companies · $13.50 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $821 · 2023: $1,140 · 2024: $57.23 · 2025: $13.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.04 | 2021-2023 | Vraylar |
| Pfizer INC. | $302.13 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $260.00 | 2021-2023 | |
| Novo Nordisk INC | $226.37 | 2021-2023 | |
| Glaxosmithkline, LLC. | $178.12 | 2022-2023 | Trelegy Ellipta |
| Amgen INC. | $174.58 | 2021-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $114.92 | 2022-2024 | |
| Lilly USA, LLC | $110.83 | 2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $74.30 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $68.01 | 2023 | Hetlioz |
| Astrazeneca Pharmaceuticals LP | $67.91 | 2023 | Farxiga, Breztri |
| Abbott Laboratories | $67.86 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $55.64 | 2022-2023 | Injectafer |
| Lucid Diagnostics INC. | $32.57 | 2023 | |
| Abiomed | $24.24 | 2023 | Impella |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.86 | 2023 | Xarelto |
| Bausch Health US, LLC | $20.80 | 2022 | |
| Merck Sharp & Dohme LLC | $20.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.06 | 2023 | Crysvita |
| Horizon Therapeutics Plc | $19.07 | 2021 | |
| Philips North America LLC | $18.53 | 2023 | |
| Averitas Pharma INC. | $18.05 | 2023 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2022 | |
| Kyowa Kirin, INC. | $16.52 | 2023 | Crysvita |
| Amarin Pharma, INC. | $14.53 | 2022 | |
| Boston Scientific Corporation | $13.50 | 2025 | General - Therapies |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.